The presence of constitutional symptoms impact prognostic scoring for myelofibrosis and is a key feature in therapy response in JAK2 inhibition, indicating the importance of the presence and mitigation of these physiologic experiences. This evidence concerns the gene JAK2 and myelofibrosis.